Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Lopatko Lindman, Karin
Publications (5 of 5) Show all publications
Lopatko Lindman, K., Lockman-Lundgren, J., Weidung, B., Olsson, J., Elgh, F. & Lövheim, H. (2022). Long-term time trends in reactivated herpes simplex infections and treatment in Sweden. BMC Infectious Diseases, 22(1), Article ID 547.
Open this publication in new window or tab >>Long-term time trends in reactivated herpes simplex infections and treatment in Sweden
Show others...
2022 (English)In: BMC Infectious Diseases, E-ISSN 1471-2334, Vol. 22, no 1, article id 547Article in journal (Refereed) Published
Abstract [en]

Background: Our aim was to describe the annual prevalence of herpes simplex virus (HSV) reactivation in relation to solar ultraviolet (UV) radiation and antiviral drug use in the Swedish adult population.

Methods: The study comprised 2879 anti-HSV-1 immunoglobulin (Ig) G positive subjects from five different cohorts who had donated serum from 1988 to 2010. The sera were analyzed for anti-HSV IgM using enzyme-linked immunosorbent assay. Associations between the presence of anti-HSV IgM antibodies, the apolipoprotein E ε4 allele and the serum sampling year were assessed by logistic regression. Seasonality of anti-HSV IgM was evaluated in a UV radiation model. Data of antiviral drugs for the entire Swedish population were compiled from two different nationwide databases: the Swedish Prescribed Drug Register and the Swedish Association of the Pharmaceutical Industry.

Results: Cross-sectional and longitudinal analyses indicated that the prevalence of anti-HSV IgM antibodies declined between 1988 and 2010 (odds ratio [OR] = 0.912, p <.001), while the total annual use of antiviral drugs in Sweden gradually increased from 1984 to 2017. Higher UV radiation was associated with higher prevalence of anti-HSV IgM antibodies (OR = 1.071, p =.043).

Conclusion: The declining time trend of HSV reactivation in a Swedish cohort coincides with a steady increase of antiviral drug use in the Swedish general population.

Place, publisher, year, edition, pages
BioMed Central (BMC), 2022
Keywords
Antiviral agents, Apolipoprotein E4, Cohort study, Epidemiology, Herpes simplex, Seroprevalence, Ultraviolet radiation
National Category
Infectious Medicine
Identifiers
urn:nbn:se:umu:diva-203316 (URN)10.1186/s12879-022-07525-w (DOI)000811753500001 ()35705911 (PubMedID)2-s2.0-85132163265 (Scopus ID)
Funder
Region VästerbottenThe Kempe FoundationsThe Dementia Association - The National Association for the Rights of the DementedHans-Gabriel och Alice Trolle-Wachtmeisters stiftelse för medicinsk forskningAlzheimerfondenGun och Bertil Stohnes Stiftelse
Available from: 2023-01-18 Created: 2023-01-18 Last updated: 2024-01-17Bibliographically approved
Lopatko Lindman, K., Jonsson, C., Weidung, B., Olsson, J., Pandey, J. P., Prokopenko, D., . . . Lövheim, H. (2022). PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer’s disease risk. Scientific Reports, 12(1), Article ID 13264.
Open this publication in new window or tab >>PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer’s disease risk
Show others...
2022 (English)In: Scientific Reports, E-ISSN 2045-2322, Vol. 12, no 1, article id 13264Article in journal (Refereed) Published
Abstract [en]

PILRA (rs1859788 A > G) has been suggested to be a protective variant for Alzheimer’s disease (AD) and is an entry co-receptor for herpes simplex virus-1. We conducted a nested case–control study of 360 1:1-matched AD subjects. Interactions between the PILRA-A allele, APOE risk variants (ε3/ε4 or ε4/ε4) and GM17 for AD risk were modelled. The associations were cross-validated using two independent whole-genome sequencing datasets. We found negative interactions between PILRA-A and GM17 (OR 0.72, 95% CI 0.52–1.00) and between PILRA-A and APOE risk variants (OR 0.56, 95% CI 0.32–0.98) in the discovery dataset. In the replication cohort, a joint effect of PILRA and PILRA × GM 17/17 was observed for the risk of developing AD (p.02). Here, we report a negative effect modification by PILRA on APOE and GM17 high-risk variants for future AD risk in two independent datasets. This highlights the complex genetics of AD.

Place, publisher, year, edition, pages
Nature Publishing Group, 2022
National Category
Medical Genetics Public Health, Global Health, Social Medicine and Epidemiology Microbiology
Identifiers
urn:nbn:se:umu:diva-198480 (URN)10.1038/s41598-022-17058-6 (DOI)000836651200031 ()35918447 (PubMedID)2-s2.0-85135234828 (Scopus ID)
Funder
EU, FP7, Seventh Framework ProgrammeRegion VästerbottenThe Kempe FoundationsThe Swedish Medical AssociationThe Dementia Association - The National Association for the Rights of the DementedAlzheimerfondenThe Swedish Brain Foundation
Available from: 2022-08-12 Created: 2022-08-12 Last updated: 2023-09-05Bibliographically approved
Lopatko Lindman, K., Hemmingsson, E.-S., Weidung, B., Brännström, J., Josefsson, M., Olsson, J., . . . Lövheim, H. (2021). Herpesvirus infections, antiviral treatment, and the risk ofdementia: a registry-based cohort study in Sweden. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 7(1), Article ID e12119.
Open this publication in new window or tab >>Herpesvirus infections, antiviral treatment, and the risk ofdementia: a registry-based cohort study in Sweden
Show others...
2021 (English)In: Alzheimer’s & Dementia: Translational Research & Clinical Interventions, E-ISSN 2352-8737, Vol. 7, no 1, article id e12119Article in journal (Refereed) Published
Abstract [en]

Introduction: Herpesviruses, including Herpes simplex virus type 1 (HSV1) and varicella zoster‐virus (VZV), have been implicated in Alzheimer's disease (AD) development. Likewise, antiviral treatment has been suggested to protect against dementia development in herpes‐infected individuals.

Methods: The study enrolled 265,172 subjects aged ≥ 50 years, with diagnoses of VZV or HSV, or prescribed antiviral drugs between 31 December 2005 and 31 December 2017. Controls were matched in a 1:1 ratio by sex and birth year.

Results: Antiviral treatment was associated with decreased risk of dementia (adjusted hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.86 to 0.92), while herpes infection without antiviral drugs increased the risk of dementia (adjusted HR 1.50, 95% CI 1.29 to 1.74).

Discussion: Antiviral treatment was associated with a reduced long‐term risk of dementia among individuals with overt signs of herpes infection. This is consistent with earlier findings indicating that herpesviruses are involved in the pathogenesis of AD.

Place, publisher, year, edition, pages
John Wiley & Sons, 2021
Keywords
Alzheimer’s disease, antiviral agents, dementia, herpes simplex, herpes zoster, retrospective cohort study, varicella zoster
National Category
Gerontology, specialising in Medical and Health Sciences
Identifiers
urn:nbn:se:umu:diva-182629 (URN)10.1002/trc2.12119 (DOI)000750546300096 ()2-s2.0-85103930201 (Scopus ID)
Available from: 2021-04-27 Created: 2021-04-27 Last updated: 2023-09-05Bibliographically approved
Lopatko Lindman, K., Weidung, B., Olsson, J., Josefsson, M., Johansson, A., Eriksson, S., . . . Lövheim, H. (2021). Plasma Amyloid-β in Relation to Antibodies Against Herpes Simplex Virus, Cytomegalovirus, and Chlamydophila pneumoniae. Journal of Alzheimer's Disease Reports, 5(1), 229-235
Open this publication in new window or tab >>Plasma Amyloid-β in Relation to Antibodies Against Herpes Simplex Virus, Cytomegalovirus, and Chlamydophila pneumoniae
Show others...
2021 (English)In: Journal of Alzheimer's Disease Reports, E-ISSN 2542-4823, Vol. 5, no 1, p. 229-235Article in journal (Refereed) Published
Abstract [en]

Background: Amyloid-β (Aβ), the key constituent of Alzheimer’s disease (AD) plaques, has antimicrobial properties.

Objective: To investigate the association between plasma Aβ and antibodies against the AD-related pathogens herpes simplex virus (HSV), cytomegalovirus (CMV), and C. pneumoniae.

Methods: Plasma from 339 AD cases, obtained on average 9.4 years (±4.00) before diagnosis, and their matched controls were analyzed for Aβ40 and Aβ42 concentrations with Luminex xMAP technology and INNOBIA plasma Aβ-form assays. Enzyme-linked immunosorbent assays were utilized for analyses of anti-HSV immunoglobulin (Ig) G, anti-HSV1 IgG, anti-HSV2 IgG, anti-CMV IgG, and anti-C. pneumoniae IgG. Follow-up samples were available for 150 of the cases.

Results: Presence and levels of anti-HSV1 IgG, anti-HSV2 IgG, anti-CMV IgG, and anti-C. pneumoniae IgG did not correlate with concentrations of Aβ42 or Aβ40 in cases or controls.

Conclusion: Levels of plasma Aβ were not associated with antibodies against different AD-related pathogens.

Place, publisher, year, edition, pages
IOS Press, 2021
Keywords
Alzheimer’s disease, amyloid-β peptides, Chlamydophila pneumoniae, cytomegalovirus, dementia, Herpes simplex, nested case-control study
National Category
Gerontology, specialising in Medical and Health Sciences
Identifiers
urn:nbn:se:umu:diva-182612 (URN)10.3233/ADR-210008 (DOI)000651079100025 ()2-s2.0-85103991159 (Scopus ID)
Available from: 2021-04-27 Created: 2021-04-27 Last updated: 2023-09-05Bibliographically approved
Lopatko Lindman, K., Weidung, B., Olsson, J., Josefsson, M., Kok, E., Johansson, A., . . . Lövheim, H. (2019). A genetic signature including apolipoprotein Eε4 potentiates the risk of herpes simplex-associated Alzheimer's disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 5, 697-704
Open this publication in new window or tab >>A genetic signature including apolipoprotein Eε4 potentiates the risk of herpes simplex-associated Alzheimer's disease
Show others...
2019 (English)In: Alzheimer’s & Dementia: Translational Research & Clinical Interventions, E-ISSN 2352-8737, Vol. 5, p. 697-704Article in journal (Refereed) Published
Abstract [en]

Introduction: Herpes simplex virus type 1 (HSV1) in combination with genetic susceptibility has previously been implicated in Alzheimer's disease (AD) pathogenesis.

Methods: Plasma from 360 AD cases, obtained on average 9.6 years before diagnosis, and their age- and sex-matched controls, were analyzed for anti-HSV1 immunoglobulin (Ig) G with enzyme-linked immunosorbent assays (ELISAs). APOE genotype and nine other selected risk genes for AD were extracted from a genome-wide association study analysis by deCODE genetics, Reykjavik, Iceland.

Results: The interaction between APOEε4 heterozygosity (APOEε24 or ε3/ε4) and anti-HSV1 IgG carriage increased the risk of AD (OR 4.55, P = .02). A genetic risk score based on the nine AD risk genes also interacted with anti-HSV1 IgG for the risk of developing AD (OR 2.35, P = .01).

Discussion: The present findings suggest that the APOEε4 allele and other AD genetic risk factors might potentiate the risk of HSV1-associated AD.

Keywords
APOEε4, Alzheimer's disease, Apolipoprotein E4, Dementia, HSV, Herpes simplex, Nested case-control study
National Category
Clinical Medicine
Research subject
Medical Virology
Identifiers
urn:nbn:se:umu:diva-167226 (URN)10.1016/j.trci.2019.09.014 (DOI)000737692800074 ()31921962 (PubMedID)2-s2.0-85074268423 (Scopus ID)
Available from: 2020-01-13 Created: 2020-01-13 Last updated: 2023-09-05Bibliographically approved
Organisations

Search in DiVA

Show all publications